BRIUMVI Reliance

Collectively, the data show TG Therapeutics heavily reliant on BRIUMVI’s U.S. sales, a strategic pivot toward subcutaneous delivery, and an emerging but still nascent cell‑therapy pipeline. The company’s financials, valuation metrics, and forthcoming product launches continue to shape investor expectations and market valuation.